PEGYLATED INSULIN LISPRO COMPOUNDS Abstract The present invention relates to the field of diabetes. More particularly the 5 invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol) are highly soluble at physiological pH have an extended duration of action and characterized by pharmacokinetic pharmacodynamic and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules to phar...

PEGYLATED INSULIN LISPRO COMPOUNDS Abstract The present invention relates to the field of diabetes. More particularly the 5 invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol) are highly soluble at physiological pH have an extended duration of action and characterized by pharmacokinetic pharmacodynamic and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules to phar...

Compositions and methods related to ester insulin or derivatives thereof are provided. The compositions include GluA4-ThrB30 ester insulin, in which side chains of GluA4 and ThrB30 of native human insulin or an insulin analogue such as insulin lispro are covalently linked via a single ester bond. The ester insulin is efficiently folded, forming the desired disulfides. The ThrB30-GluA4 ester bond can be cleaved in vitro or in vivo to give the desired folded insulin with full biological activity. ...

The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them...